Biodel
Danbury
About Biodel
Biodel Inc. (Biodel) is a development-stage company. The Company is a biopharmaceutical company focused on the development and commercialization of treatments for diabetes. It develops its product candidates by applying its formulation technologies to existing drugs. Its product candidate is Linjeta. It has formulated Linjeta as rapid-acting mealtime insulin for the treatment of patients with Type I and Type II diabetes. Earlier stage product candidates include follow-on and second generation rapid-acting mealtime insulins or insulin analogs, VIAtab, a sublingual tablet formulation of insulin, a line of basal insulins, and a formulation of glucagon.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $48.5M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jun 2012)
- Ticker: nasdaq:BIOD
- Website: biodel.com
- Phone: 2037965003
Industries & Categories
Biotechnology, Developer Platform, Health Care
Social Profiles
Canonical: https://fsome.com/organization/biodel-1023358 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.